Islander News1d
AstraZeneca's FluMist influenza vaccine, which can be self-administered. Experts hope an option for at-home flu vaccination will boost uptake
AstraZeneca's FluMist influenza vaccine, which can be self-administered. Experts hope an option for at-home flu vaccination ...
US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
On Friday, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers ...
Nasal flu vaccine is approved for at-home use
The FDA authorized AstraZeneca’s treatment to be given outside a health care setting, although it will still need a prescription.
STAT1d
FDA approves first at-home flu vaccine in U.S., a nasal spray
FluMist is the only flu vaccine administered by nasal spray, not injection. It is licensed for individuals between the ages ...
AstraZeneca’s Fasenra to challenge GSK’s Nucala in rare vasculitis after FDA nod
Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...
AstraZeneca’s Fasenra meets primary endpoint in Phase III rare vasculitis trial
The Phase III trial compared the efficacy of Fasenra with the standard treatment of GSK’s Nucala in patients with ...
Pharmabiz3d
US FDA approves AstraZeneca’s Fasenra to treat eosinophilic granulomatosis with polyangiitis
AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated ...
Managed Healthcare Executive3d
FDA Approves Fasenra for Treatment of Eosinophilic Granulomatosis with Polyangiitis
More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.
MedPage Today4d
FDA OKs New Option for Rare Immune-Mediated Vasculitis
EGPA, previously known as Churg-Strauss syndrome, is a rare inflammatory disorder characterized by asthma, necrotizing ...
The American Journal of Managed Care4d
FDA Approves Benralizumab for Eosinophilic Granulomatosis With Polyangiitis
The FDA approved benralizumab (Fasenra) for adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...
EuropaWire4d
FDA Approves AstraZeneca’s Fasenra for Eosinophilic Granulomatosis with Polyangiitis, Offering New Hope for Patients
AstraZeneca's Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with ...